MedTrace Logo

Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes

NCT03968809 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 101

Last updated 2023-02-23

No results posted yet for this study

Summary

This single-center clinical trial is designed to evaluate the CardioFlux magnetocardiograph diagnostic imaging system to predict major adverse cardiac events (MACE) in patients referred for evaluation for coronary artery disease.

Conditions

Interventions

DIAGNOSTIC_TEST

CardioFlux Magnetocardiography

All patients enrolled and receiving standard screening tests for CAD will undergo a 2 minute scan with MCG. It will be determined if MCG scanning can provide equal or superior accuracy to predict MACE than standard testing.

Sponsors & Collaborators

  • Genetesis Inc.

    lead INDUSTRY

Principal Investigators

  • Partho P Sengupta, M.D. · WVU Heart and Vascular Institute, J.W. Ruby Memorial Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-05
Primary Completion
2020-06-20
Completion
2020-06-20
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03968809 on ClinicalTrials.gov